

## **Fiscal Note H.B. 156**2015 General Session Medicaid Preferred Drug List Amendments by Ward, R.



## General, Education, and Uniform School Funds

JR4-5-101

	Ongoing	One-time	Total
Net GF/EF/USF (revexp.)	\$1,405,800	\$(1,100,000)	\$305,800

State Government UCA 36-12-13(2)(b)

Enactment of this legislation likely will not materially impact state revenue.					
Revenues	FY 2015	FY 2016	FY 2017		
Total Revenues	\$0	\$0	\$0		

Enactment of this legislation may reduce expenditures for prescription drugs in the Medicaid program for the Department of Health one-time by \$300,000 General Fund and \$710,800 federal funds in FY 2016 and ongoing \$1,400,000 General Fund and \$3,317,000 federal funds in FY 2017. By FY 2021 ongoing General Fund savings may be \$4,000,000 and federal fund savings of \$9,500,000. Enactment of this legislation may reduce the cost of some drugs used at the Department of Human Services' Utah State Developmental Center by \$5,800 ongoing General Fund beginning in FY 2016.

Expenditures	FY 2015	FY 2016	FY 2017
General Fund	\$0	\$(1,405,800)	\$(1,405,800)
Federal Funds	\$0	\$(710,800)	\$(3,317,000)
General Fund, One-Time	\$0	\$1,100,000	\$0
Total Expenditures	\$0	\$(1,016,600)	\$(4,722,800)
Net All Funds	\$0	\$1,016,600	\$4,722,800

Local Government UCA 36-12-13(2)(c)

Enactment of this legislation likely will not result in direct, measurable costs for local governments.

## Individuals & Businesses

UCA 36-12-13(2)(d)

Enactment of this legislation likely will not result in direct, measurable expenditures by Utah residents or businesses.

Performance Note JR4-2-404

No performance note required for this bill

## **Notes on Notes**

Fiscal notes estimate the direct costs or revenues of enacting a bill. The Legislature uses them to balance the budget. They do not measure a bill's benefits or non-fiscal impacts like opportunity costs, wait times, or inconvenience. A fiscal note is not an appropriation. The Legislature decides appropriations separately.